The metabolic myopathies are a heterogeneous group of diseases characterized by impaired skeletal muscle energy production. Primary metabolic myopathies are associated with genetically determined defects in glycogen and lipid metabolism and in mitochondrial oxidative phosphorylation. These include the muscle glycogenoses and the lipid and mitochondrial myopathies. Other metabolic myopathies arise from endocrine or electrolyte abnormalities and therapy with specific drugs. A classification of the primary metabolic myopathies is presented in Table 19-1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vladutiu GD. The molecular diagnosis of metabolic myopathies. Neurol Clin 2000;18:53–104.
DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve 2001;24:984–999.
Vissing J, Haller RG. The effect of oral sucrose on exercise tolerance in patients with McArdle’s disease. N Engl J Med 2003;349:2503–2509.
Livingstone C, Chinnery PF, Turnbull DM. The ischaemic lactate-ammonia test. Ann Clin Biochem 2001;38:304–310.
Wortmann RL, DiMauro S. Differentiating idiopathic inflammatory myopathies from metabolic myopathies. Rheum Dis Clin North Am 2002;28:759–778.
Greenberg SA, Walsh RJ. Molecular diagnosis of inher-itable neuromuscular disorders. Part II: application of genetic testing in neuromuscular disease. Muscle Nerve 2005;31:431–451.
Kiechl S, Kohlendorfer U, Thaler C, et al. Different clinical aspects of debrancher deficiency myopathy. J Neurol Neurosurg Psychiatry 1999;67:364–368.
Amato AA. Acid maltase deficiency and related myopathies. Neurol Clin 2000;18:151–165.
Winkel LP, Hagemans ML, van Doorn PA, et al. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J Neurol 2005;252:875–884.
Haller RG, Lewis SF. Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med 1991;324:364–369.
Wang Y, Ye J, Ganapathy V, Longo N. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci USA 1999;96:2356–2360.
Cwik VA. Disorders of lipid metabolism in skeletal muscle. Neurol Clin 2000;18:167–184.
Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol 2005;62:37–41.
Olpin SE. Fatty acid oxidation defects as a cause of neuromyopathic disease in infants and adults. Clin Lab 2005;51:289–306.
DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003;348:2656–2668.
Nardin RA, Johns DR. Mitochondrial dysfunction and neuromuscular disease. Muscle Nerve 2001;24:170–191.
Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG. The spectrum of exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain 2003;126:413–423.
Tarnopolsky MA, Raha S. Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med Sci Sports Exerc 2005;37:2086–2093.
Taylor RW, Schaefer AM, Barron MJ, McFarland R, Turnbull DM. The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 2004;14:237–245.
Tarnopolsky MA, Parise G, Gibala MJ, Graham TE, Rush JW. Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J Physiol 2001;533:881–889.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Baer, A.N. (2008). Metabolic Myopathies. In: Klippel, J.H., Stone, J.H., Crofford, L.J., White, P.H. (eds) Primer on the Rheumatic Diseases. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68566-3_19
Download citation
DOI: https://doi.org/10.1007/978-0-387-68566-3_19
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-35664-8
Online ISBN: 978-0-387-68566-3
eBook Packages: MedicineMedicine (R0)